Yongan Pharmaceutical: The company's stock price has significantly deviated from the overall market trend in the short term, and there is a high risk of speculation.

On June 15, Yong'an Pharmaceutical announced that the recent short-term increase in the company's stock price has significantly deviated from the overall market trend, posing a high speculative risk. However, there have been no major changes in the company's fundamentals, and there is no undisclosed significant information that should be disclosed. In the first quarter of 2025, the company was in a loss-making state. According to the data from China Securities Index Co., Ltd., as of the disclosure of this announcement, the company's latest static price-to-book ratio, rolling price-to-earnings ratio, and price-to-book ratio are all higher than the industry average of "pharmaceutical manufacturing" to which the company belongs. The company has issued multiple announcements of abnormal fluctuations in stock trading for several consecutive days, especially reminding investors to pay attention to the risks in the secondary market trading, make rational decisions, and invest cautiously.